Michael King
Stock Analyst at EF Hutton
(0.80)
# 3,851
Out of 4,941 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $5.74 | +11,224.04% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $2.99 | +39,338.13% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.45 | +147.19% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.65 | +1,839.39% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $2.85 | +2,303.51% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $11.10 | +1,701.80% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.19 | +597.48% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $556.56 | +54.88% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $37.95 | -36.76% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $4.81 | +3,351.14% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $7.75 | +441.94% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $429.93 | -29.29% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $10.86 | +968.14% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.17 | +224.92% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $32.20 | -25.47% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.55 | +145,354.55% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $20.09 | +128.97% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $35.38 | +171.34% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.70 | +5,042.86% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $11.56 | +168.28% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $637.40 | -94.35% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $5.74
Upside: +11,224.04%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $2.99
Upside: +39,338.13%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.45
Upside: +147.19%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.65
Upside: +1,839.39%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $2.85
Upside: +2,303.51%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $11.10
Upside: +1,701.80%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.19
Upside: +597.48%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $556.56
Upside: +54.88%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $37.95
Upside: -36.76%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.81
Upside: +3,351.14%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $7.75
Upside: +441.94%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $429.93
Upside: -29.29%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $10.86
Upside: +968.14%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $3.17
Upside: +224.92%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $32.20
Upside: -25.47%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.55
Upside: +145,354.55%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $20.09
Upside: +128.97%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $35.38
Upside: +171.34%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.70
Upside: +5,042.86%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $11.56
Upside: +168.28%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $637.40
Upside: -94.35%